首页> 外文期刊>Digestive Diseases and Sciences >Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis.
【24h】

Protective effects of baicalin and octreotide on multiple organ injury in severe acute pancreatitis.

机译:黄ical苷和奥曲肽对重症急性胰腺炎多器官损伤的保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To discuss the application value of Baicalin which is a new drug by comparing the protecting effects of Baicalin and Octreotide on multiple organs (pancreas, liver, kidney, and lung) in Severe acute pancreatitis (SAP). METHODS: The improved Aho method was adopted to prepare SAP rat models via retrograde injection of 3.5% sodium taurocholate to the pancreatic duct. The 135 SAP rat models after being prepared were randomly divided into the model group, Baicalin treatment group and Octreotide treatment group with 45 rats in each group; another 45 were selected to be the sham operation group, which only received abdomen opening surgery. The groups were then randomly divided into 3 h, 6 h and 12 h groups with 15 rats in each group, 10 min after successful modeling, the Baicalin treatment group was first injected with a 5% Baicalin injection at a dose of 10 mg/100 g via external jugular-vein passage followed by continuous intravenous administration (10 mg/h/100 g) by microinfusion pump; the Octreotide treatment group was first injected by Octreotide at a dose of 0.2 ug/100 g via external jugular-vein passage followed by continuous intravenous transfusion (10 mg/h/100 g) by microinfusion pump at a transfusion speed of 0.2 ug/h/100 g. The sham operation group and model group were injected with saline of equivalent volume at the corresponding time points after operation. The following observations were carried out 3, 6 and 12 h after operation: (1) mortalities of all rat groups followed by batch execution of rats and observation of the gross pathological changes of multiple organs; (2) observation of the pathological changes of multiple organ samples fixed according to the relevant requirements after HE staining; and (3) serum content of amylase, NO, malonaldehyde (MDA), and tumor necrosis factor alpha (TNF-alpha). RESULTS: (1) The survival rate of the sham operation group and all treatment groups was 100%, whilst the 12 h survival of the model group was 66.67% (10/15), indicating a significant difference (P < 0.05). (2) The gross pathological changes and changes under light microscopy of multiple organs aggravated with time after modeling. The pathological changes of all treatment groups were milder than those of the model group at different time points by various degrees, most obviously at 6 h and 12 h. The gross pathological changes showed a similarity between the Octreotide and Baicalin treatment groups in terms of the pathological changes of pancreatic tissue. The therapeutic effects of Octreotide on kidney and lung were superior to those in the Baicalin treatment group while the pathological manifestations of the Baicalin treatment group were superior to those of the Octreotide treatment group. (3) There was no marked difference between the Baicalin and Octreotide treatment groups in terms of plasma amylase levels at all time points (P > 0.05). Although the plasma amylase levels of the Baicalin treatment group were lower than those of the model group at all time points, the levels in the Baicalin treatment group were significantly lower than those in the model group only at 3 h (P < 0.05), and there was no marked difference in the levels between the Baicalin treatment group and model groups at 6 and 12 h (P > 0.05); the levels in the Octreotide treatment group were significantly lower than in the model group at 6 h (P < 0.05), and there was no marked difference between the levels in the Octreotide treatment group and model group at 3 h and 12 h (P > 0.05). (4) The serum NO contents of the Baicalin treatment group were significantly lower than those of the model group (P < 0.05), while in the Octreotide treatment group it was obviously lower than in the model group at 3 and 12 h (P < 0.01); in this regard there was no marked difference between the Baicalin and Octreotide treatment groups at different time points (P > 0.05). (5) The serum MDA contents of the Baicalin treatment group were significantly lower than those of t
机译:目的:通过比较黄ical苷和奥曲肽对严重急性胰腺炎(SAP)中多种器官(胰腺,肝,肾和肺)的保护作用,探讨黄ical苷的新药应用价值。方法:采用改良的Aho法向胰管逆行注射3.5%牛磺胆酸钠,制备SAP大鼠模型。将135只SAP大鼠模型随机分为模型组,黄ical苷治疗组和奥曲肽治疗组,每组45只。另选45例作为假手术组,仅接受腹部开放手术。然后将各组随机分为3h,6h和12h组,每组15只大鼠,在成功建模后10分钟,向黄ical苷治疗组首先注射5%黄Ba苷注射液,剂量为10 mg / 100 g通过颈静脉外通道,然后通过微输液泵连续静脉内给药(10 mg / h / 100 g);首先将奥曲肽治疗组以0.2 ug / 100 g的剂量通过外颈静脉通过奥曲肽注射,然后通过微输液泵以0.2 ug / h的速度连续静脉输注(10 mg / h / 100 g) /100克。假手术组和模型组在手术后的相应时间点注射等量的生理盐水。术后3、6、12 h进行以下观察:(1)所有组的死亡率,然后分批处死大鼠,观察多器官的总体病理变化; (2)观察HE染色后根据相关要求固定的多个器官标本的病理变化; (3)淀粉酶,NO,丙二醛(MDA)和肿瘤坏死因子α(TNF-alpha)的血清含量。结果:(1)假手术组和所有治疗组的生存率为100%,模型组的12 h生存率为66.67%(10/15),差异有统计学意义(P <0.05)。 (2)建模后,随着时间的推移,大的病理变化和多个器官的光学显微镜下的变化随时间而加重。在不同时间点,所有治疗组的病理变化均轻于模型组,不同程度,最明显的是在6 h和12 h。就胰腺组织的病理变化而言,总体病理变化显示奥曲肽和黄ical苷治疗组之间具有相似性。奥曲肽对肾和肺的治疗效果优于黄ical苷治疗组,而黄ical苷治疗组的病理表现优于奥曲肽治疗组。 (3)在所有时间点,黄ical苷和奥曲肽治疗组之间的血浆淀粉酶水平均无显着差异(P> 0.05)。尽管黄ical苷治疗组的血浆淀粉酶水平在所有时间点均低于模型组,但仅在3 h时黄am苷治疗组的血浆淀粉酶水平显着低于模型组(P <0.05),并且黄ical苷治疗组和模型组在第6和12 h时的水平无显着差异(P> 0.05)。在6 h时奥曲肽治疗组的水平显着低于模型组(P <0.05),在3 h和12 h奥曲肽治疗组与模型组的水平没有显着差异(P> 0.05)。 0.05)。 (4)黄ical苷治疗组的血清NO含量明显低于模型组(P <0.05),而奥曲肽治疗组在3和12 h时血清NO含量明显低于模型组(P <0.05)。 0.01);在这方面,黄ical苷和奥曲肽治疗组在不同时间点之间没有显着差异(P> 0.05)。 (5)黄ical苷治疗组的血清MDA含量明显低于tical组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号